Gelatin‐coated Gold Nanoparticles as Carriers of FLT3 Inhibitors for Acute Myeloid Leukemia Treatment. (22nd February 2016)

• Record Type: Journal Article
• Authors: Suarasan, Sorina; Simon, Timea; Boca, Sanda; Tomuleasa, Ciprian; Astilean, Simion
• Is Part Of: Chemical biology & drug design. Volume 87:Number 6(2016)
• Page Start: 927
• Page End: 935
• Publication Date: 2016-02-22
• Subjects: cancer -- colloid -- drug design -- drug transport -- nanoparticles -- nanotechnology; Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.12725
• Languages: English
• ISSNs: 1747-0277

Abstract

Abstract : This study presents the design of a gold nanoparticle (AuNPs)—drug system with improved efficiency for the treatment of acute myeloid leukemia. The system is based on four different FLT3 inhibitors, namely midostaurin, sorafenib, lestaurtinib, and quizartinib, which were independently loaded onto gelatin‐coated gold nanoparticles. Detailed investigation of the physicochemical properties of the formed complexes lead to the selection of quizartinib—loaded AuNPs for the in vitro evaluation of the biological effects of the formed complex against OCI‐AML3 acute myeloid leukemia cells. Viability tests by MTT demonstrated that the proposed drug complex has improved efficacy when compared with the drug alone. The obtained results constitute a premise for further in vivo investigation of such drug vehicles based on AuNPs. To the best of our knowledge, this is the first study that investigates the delivery of the above‐mentioned FLT3 inhibitors via gelatin‐coated gold nanoparticles. Abstract : The design of a gold nanoparticle (AuNPs) drug system with improved efficiency for the treatment of acute myeloid leukemia is presented in this study. Four different FLT3 inhibitors, namely midostaurin, sorafenib, lestaurtinib, and quizartinib, were independently loaded onto gelatin‐coated AuNPs. Quizartinib‐loaded AuNPs were selected for the in vitro evaluation of the biological effects of complex against OCI‐AML3 and THP‐1 acute myeloid leukemia cells. Viability tests by MTT demonstrated that the proposed drug complex has improved efficacy when compared with the drug alone.